Yield10 Bioscience Inc. [NASDAQ: YTEN] stock went on an upward path that rose over 4.97% on Tuesday, amounting to a one-week price increase of more than 5.65%. The company report on August 11, 2020 that Yield10 Bioscience Announces Second Quarter 2020 Financial Results.
Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three and six months ended June 30, 2020.
“The Yield10 team has made good progress executing on our strategic plans for 2020 and beyond,” said Oliver Peoples, Ph.D., president and chief executive officer of Yield10 Bioscience. “Our field tests in the U.S. and Canada are progressing on track and will provide us with agronomic and/or performance data proof points as well as seed for larger trials planned in 2021. As part of our business plan to develop Camelina as a commercial crop platform for producing nutritional oils and PHA biomaterial, we are developing proprietary double haploid germplasm for deployment of our performance and product traits in winter and spring varieties to increase the acreage potential of the crop. In our first multi-acre planting, we contracted 50 acres in Montana of wild-type Camelina to gain experience in seed bulk-up, grower contracts, logistics and handling of harvested seed, including toll crushing, and to produce quantities of oil and protein meal for customer sampling.”.
Over the last 12 months, YTEN stock dropped by -84.84%. The average equity rating for YTEN stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $13.03 million, with 1.70 million shares outstanding and 1.54 million shares in the current float. Compared to the average trading volume of 142.73K shares, YTEN stock reached a trading volume of 2302313 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Yield10 Bioscience Inc. [YTEN]:
National Securities have made an estimate for Yield10 Bioscience Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 18, 2019. The new note on the price target was released on May 31, 2019, representing the official price target for Yield10 Bioscience Inc. stock. Previously, the target price had yet another raise to $7, while Maxim Group analysts kept a Buy rating on YTEN stock.
The Average True Range (ATR) for Yield10 Bioscience Inc. is set at 0.49, with the Price to Sales ratio for YTEN stock in the period of the last 12 months amounting to 14.48. The Price to Book ratio for the last quarter was 1.19, with the Price to Cash per share for the same quarter was set at 4.92.
YTEN Stock Performance Analysis:
Yield10 Bioscience Inc. [YTEN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.65. With this latest performance, YTEN shares gained by 8.44% in over the last four-week period, additionally sinking by -17.71% over the last 6 months – not to mention a drop of -84.84% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for YTEN stock in for the last two-week period is set at 54.67, with the RSI for the last a single of trading hit 59.07, and the three-weeks RSI is set at 53.47 for Yield10 Bioscience Inc. [YTEN]. The present Moving Average for the last 50 days of trading for this stock 6.41, while it was recorded at 6.33 for the last single week of trading, and 6.74 for the last 200 days.
Insight into Yield10 Bioscience Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Yield10 Bioscience Inc. [YTEN] shares currently have an operating margin of -1066.50. Yield10 Bioscience Inc.’s Net Margin is presently recorded at -1607.44.
Return on Total Capital for YTEN is now -293.93, given the latest momentum, and Return on Invested Capital for the company is -493.84. Return on Equity for this stock declined to -1,591.65, with Return on Assets sitting at -104.01. Additionally, YTEN Total Debt to Total Capital is recorded at 3,103.68, with Total Debt to Total Assets ending up at 25.25.
Reflecting on the efficiency of the workforce at the company, Yield10 Bioscience Inc. [YTEN] managed to generate an average of -$518,240 per employee. Receivables Turnover for the company is 6.40 with a Total Asset Turnover recorded at a value of 0.06.Yield10 Bioscience Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.80 and a Current Ratio set at 4.80.
YTEN Stock EPS
With the latest financial reports released by the company, Yield10 Bioscience Inc. posted -6.4/share EPS, while the average EPS was predicted by analysts to be reported at -6.6/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 3.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for YTEN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Yield10 Bioscience Inc. go to 0.00%.
Yield10 Bioscience Inc. [YTEN] Insider Position Details
There are presently around $1 million, or 7.60% of YTEN stock, in the hands of institutional investors. The top three institutional holders of YTEN stocks are: CANNELL PETER B & CO INC with ownership of 53,125, which is approximately 0% of the company’s market cap and around 1.00% of the total institutional ownership; BLACKROCK INC., holding 37,699 shares of the stock with an approximate value of $0.25 million in YTEN stocks shares; and BIRCHVIEW CAPITAL, LP, currently with $0.12 million in YTEN stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Yield10 Bioscience Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 3 institutional holders increased their position in Yield10 Bioscience Inc. [NASDAQ:YTEN] by around 2,186 shares. Additionally, 8 investors decreased positions by around 28,433 shares, while 6 investors held positions by with 89,858 shares. The mentioned changes placed institutional holdings at 120,477 shares, according to the latest SEC report filing. YTEN stock had 2 new institutional investments in for a total of 5 shares, while 6 institutional investors sold positions of 25,261 shares during the same period.